IDC-002

N/A

Report date: 2023/08/25 17:09:50

First In Class

Base Information

Drug NameIDC-002

Drug Alias NameIDC-002IDC002

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsPancreatic adenocarcinoma upregulated factor inhibitors

TargetsPancreatic adenocarcinoma upregulated factor

Therapy Area/IndicationsOvarian NeoplasmsPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySingapore

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPrestige BioPharma Ltd

China Registration ClassN/A

Develop Information

Active CompaniesPrestige BioPharma Ltd

Inactive CompaniesN/A

Active IndicationsOvarian NeoplasmsPancreatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A